Desmopressin
Desmopressin.JPG

Desmopressin

CLINICAL USE

Diabetes insipidus Nocturnal enuresis Post-biopsy bleeding (unlicensed indication)Pre-biopsy prophylaxis (unlicensed indication)

DOSE IN NORMAL RENAL FUNCTION

Diabetes insipidus: Oral: 0.2–1.2 mg daily in 3 divided doses. IV: 1–4 mcg daily. Inhaled: 10–40 mcg in 1 or 2 divided doses. Sub-lingual: 120–720 mcg dailyNocturnal enuresis: Oral: 200–400 mcg at bedtime, Biopsy: Males – 16 mcg; Females – 12 mcg or 300–400 nanograms/kg Pre-biopsy prophylaxis in uraemic patients: 20 mcg (IV) over 30 minutes

PHARMACOKINETICS

  • Molecular weight                           :1069.2
  • %Protein binding                           :0
  • %Excreted unchanged in urine     : 45
  • Volume of distribution (L/kg)       :0.2–0.41
  • half-life – normal/ESRD (hrs)      :Inhaled: 55 minutes; Oral: 2.8 hours; IV: 51–158 minutes/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION

    Reconstition

    Dilute dose to 50 mL with sodium chloride 0.9%

    Route

    IV, intranasally, oral, SC, IM, SL

    Rate of Administration

    Over 20–60 minutes

    Comments

    Do not inject at a faster rate – greater risk of tachyphylaxisIn patients with ischaemic heart disease, infuse more slowly – increased risk of acute ischaemic event

    OTHER INFORMATION

    Emergency treatment of more generalised bleeding unresponsive to normal treatments: 0.1–0.5 micrograms/kg 4 times a day + IV conjugated oestrogens (premarin) 0.6 mg/kg/day for up to 5 days DDAVP works as a haemostatic by stimulating factor VIII production Onset of action less than 1 hour. Duration of effect 4–8 hours



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs